Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI

Poster Presenter: Deepak Rath, MBBS, MD, Postgraduate Resident, John H. Stroger, Jr. Hospital of Cook County

Poster Title: Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI

Poster Session C: 10:30 a.m.–12:30 p.m. on Tuesday, October 28

What is your poster about?

“My poster presents the clinical and serological profile of patients with primary Sjögren’s syndrome, with a focus on systemic disease activity using the EULAR Sjögren’s syndrome disease activity index (ESSDAI) tool. It highlights symptom patterns, laboratory findings, and the associations between specific autoantibodies and domain-specific involvement.”

Why did you decide to investigate this topic?

“Sjögren’s syndrome is often underdiagnosed and thought of mainly as a glandular disease, yet systemic involvement can be significant. By studying how different autoantibodies relate to organ-specific activity, we aimed to better understand disease heterogeneity and improve monitoring strategies.”

What are you working on next related to this research?

“We are planning to follow up with these patients longitudinally to evaluate how autoantibody profiles predict disease progression, organ involvement, and treatment response. We also hope to expand the cohort to validate these associations in a larger, more diverse population.”

What excites you most about your work?

“I am excited that this research helps bridge clinical findings with laboratory data, potentially allowing us to personalize care. Identifying antibody-disease domain correlations may improve early detection of systemic complications and guide more targeted management.”

What are you most looking forward to at ACR Convergence 2025 in Chicago?

“I am looking forward to sharing ideas with colleagues, learning about the latest advances in Sjögren’s syndrome and other systemic autoimmune diseases, and gaining insights into novel diagnostic and therapeutic approaches that could benefit my patients.”